Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | EPOR | P19235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7600355 | 0.92 | CA1 (0.45) | FOLH1HTTSLC1A3SLC1A1 | |
| SCHEMBL7597929 | 0.92 | CA1 (0.45) | FOLH1HTTSLC1A3SLC1A1 | |
| SCHEMBL7597839 | 0.91 | FOLH1 (0.49) | FOLH1HTTSLC1A3SLC1A1 | |
| SCHEMBL7595812 | 0.91 | FOLH1 (0.49) | FOLH1HTTSLC1A3SLC1A1 | |
| SCHEMBL7600882 | 0.90 | TRPM8 (0.41) | TRPM8FOLH1PSMB5MTNR1AMTNR1B | |
| SCHEMBL7600868 | 0.90 | FOLH1 (0.45) | FOLH1PSMB5HTTSLC1A3SLC1A1 | |
| SCHEMBL7600890 | 0.89 | FOLH1 (0.43) | FOLH1HTTSLC1A3SLC1A1 | |
| SCHEMBL7597117 | 0.88 | FOLH1 (0.46) | FOLH1HTTSLC1A3SLC1A1 | |
| SCHEMBL7595116 | 0.88 | FOLH1 (0.46) | FOLH1HTTSLC1A3SLC1A1 | |
| SCHEMBL7598385 | 0.88 | TRPM8 (0.44) | TRPM8FOLH1PSMB5MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1017672-B1 | NEW NPY ANTAGONISTS | ASTRAZENECA AB (SE) | 2002-11-27 | — | — | EP | disclosed |